Ultragenyx Pharma (RARE) Tops Q3 EPS by 33c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.08), $0.33 better than the analyst estimate of ($1.41). Revenue for the quarter came in at $81.6 million versus the consensus estimate of $81.55 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Ultragenyx Pharma (RARE) PT Raised to $83 at Canaccord
• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• Vireo Growth completes acquisition of C21 Investments